People: Aastrom Biosciences Inc (ASTM.OQ)

ASTM.OQ on NASDAQ Stock Exchange Capital Market

3.24USD
25 Jul 2014
Price Change (% chg)

$-0.10 (-2.99%)
Prev Close
$3.34
Open
$3.31
Day's High
$3.31
Day's Low
$3.23
Volume
2,906
Avg. Vol
35,472
52-wk High
$17.79
52-wk Low
$3.10

Search Stocks

Summary

Name Age Since Current Position

Robert Zerbe

62 2012 Independent Chairman of the Board

Dominick Colangelo

2014 President, Chief Executive Officer, Chief Accounting Officer, Treasurer, Director

Gerard Michel

51 2014 Chief Financial Officer, Vice President - Corporate Development

Daniel Orlando

47 2013 Chief Operating Officer, Chief Business Officer, Chief Commercial Officer

Ross Tubo

2014 Chief Scientific Officer

David Recker

2014 Chief Medical Officer

Heidi Hagen

2013 Director

Timothy Mayleben

53 2012 Director

Alan Rubino

58 2005 Independent Director

Nelson Sims

65 2012 Independent Director

Biographies

Name Description

Robert Zerbe

Dr. Robert L. Zerbe, M.D., is Independent Chairman of the Board of Aastrom Biosciences, Inc. He has been a Director since January 2006 and Chairman of the Board of Directors since October 2012, is the Chief Executive Officer of QUATRx Pharmaceuticals Company, a venture-backed drug development company which he co-founded in 2000. Prior to his role at QUATRx, Dr. Zerbe held several senior executive management positions with pharmaceutical companies including Eli Lilly (from 1982 to 1993) and Pfizer (formerly Parke-Davis) (from 1993 to 2000). During his tenure at Eli Lilly, Dr. Zerbe’s clinical research and development positions included Managing Director, Lilly Research Center U.K., and Vice President of Clinical Investigation and Regulatory Affairs. He joined Parke Davis in 1993, becoming Senior Vice President of Worldwide Clinical Research and Development. In this capacity he led the clinical development programs for a number of key products, including Lipitor ® and Neurontin ®. Dr. Zerbe received his M.D. from the Indiana University School of Medicine, and has completed post-doctoral work in internal medicine, endocrinology and neuroendocrinology at Indiana University and the National Institutes of Health. Dr. Zerbe currently serves on the board of directors of Optimer Pharmaceuticals, Inc. (since 2009), a biopharmaceutical company. He also serves on the board of directors of, Edgemont Pharmaceuticals, a private specialty pharma company.

Dominick Colangelo

Mr. Dominick C. Colangelo is President, Chief Executive Officer, Chief Accounting Officer, Treasurer, Director of Aastrom Biosciences Inc. Mr. Colangelo joined Aastrom in 2013 with more than twenty years of executive management and corporate development experience in the biopharmaceutical industry, including nearly a decade with Eli Lilly and Company. Most recently, he was President and Chief Executive Officer of Promedior, Inc. During his career, he has held a variety of executive positions of increasing responsibility in product development, pharmaceutical operations, sales and marketing, and corporate development. He has experience in the acquisition, development and commercialization of therapies to treat fibrovascular, metabolic and cardiovascular diseases. During his tenure at Eli Lilly and Company, he held positions as Director of Strategy and Business Development for Lilly’s Diabetes Product Group and also served as a founding Managing Director of Lilly Ventures. Mr. Colangelo received his B.S.B.A. in Accounting, Magna Cum Laude, from the State University of New York at Buffalo and a J.D. degree, with Honors, from the Duke University School of Law.

Gerard Michel

Mr. Gerard Michel is Chief Financial Officer, Vice President - Corporate Development of the Company Mr. Michel was formerly CFO and VP, Corporate Development of Biodel from November 2007 to May 2014 where he oversaw strategic development, fundraising and capital structure management, marketing efforts, investor management, and financial reporting and internal controls. From August 2002 to November 2007, Mr. Michel served as Chief Financial Officer, VP of Corporate Development of NPS Pharmaceuticals, where he led the first syndicated royalty monetization, the structure of which has been widely copied and used to create new sources of capital for biotechnology companies. He received his bachelor’s degree with a major in Biology and Geology from the University of Rochester, his master’s degree from the University of Rochester School of Medicine and Dentistry and an M.B.A. from the Simon School of Business at the University of Rochester.

Daniel Orlando

Mr. Daniel R. Orlando is Chief Operating Officer, Chief Business Officer, Chief Commercial Officer of Aastrom Biosciences, Inc. He was appointed as Chief Operating Officer of the Company on August 23, 2013. Mr. Orlando has been serving as Chief Commercial Officer of the Company since August 2012 and as the Chief Business Officer of the Company since May 2013. He also served as the Company’s interim Chief Executive Officer from December 2012 to March 2013. He has more than 20 years of commercial product preparation and launch experience including leadership roles in sales, marketing and most recently as a vice president of business development for North and South America at Takeda Pharmaceuticals. As an early employee at Takeda North America, he served as the original brand director for Actos, which became the #1 branded anti-diabetic agent in the U.S. Mr. Orlando’s initial pharmaceutical experience came in progressively expanding roles in sales and marketing at Abbott Laboratories. He holds an MBA from Florida Atlantic University and a BA in economics with Honors from the University of Florida.

Ross Tubo

Dr. Ross Tubo has been appointed as Chief Scientific Officer of the Company, effective April 1, 2014. Dr. Tubo was formerly vice president of stem cell and chemokine biology at Genzyme, where he directed the research and development programs for two of the first FDA-approved autologous cellular therapies. He also led an interdisciplinary research program to study the cellular and molecular biology of mesenchymal stem cells and their reparative properties in a range of areas, including oncology, inflammation and autoimmune disease. Additionally, as founder of Research Translation, LLC, Dr. Tubo provided senior level consulting services to several leading companies developing cell therapies and regenerative medicines. He received his doctorate and master’s degree from the State University of New York at Buffalo and completed a postdoctoral fellowship at Harvard Medical School.

David Recker

Dr. David Recker has been appointed as Chief Medical Officer of the Company. Dr. Recker joins Aastrom with more than 20 years of experience in drug development. He most recently served as a senior vice president of clinical sciences at Takeda Global Research and Development, where he led a multi-regional clinical organization responsible for designing and implementing global clinical development strategies for a variety of products in a range of therapeutic areas. Dr. Recker has played a lead role in multiple successful global regulatory filings. He holds an MD with distinction from the University of Michigan, where he was chief resident in internal medicine. He completed his fellowship at the National Institutes of Health.

Heidi Hagen

Ms. Heidi Hagen has been appointed as Director of Aastrom Biosciences, Inc., effective August 23, 2013. Ms. Hagen is global chief operating officer at Sotio LLC, a biotechnology company developing new therapies for the treatment of cancer and autoimmune diseases using its immunotherapy platform and proprietary cell-based technologies. Previously Ms. Hagen was senior vice president, operations, at Dendreon Corporation, where she was responsible for, among other duties, manufacturing and supply chain operations. Prior to joining Dendreon, Ms. Hagen spent nearly ten years at Immunex Corporation, where she held several positions in drug development and supply chain and operations management. Ms. Hagen earned her B.S. in cell and molecular biology, M.S. in bioengineering, and MBA at the University of Washington.

Timothy Mayleben

Mr. Timothy M. Mayleben is Director of Aastrom Biosciences Inc. Mr. Mayleben is a Director since June 2005, has served as Aastrom’s President and Chief Executive Officer (the “CEO”) since December 2009. Mr. Mayleben served as an advisor to life science and healthcare companies through his advisory and investment firm, ElMa Advisors since 2004. Previously, he served as the President and Chief Operating Officer and a Director of NightHawk Radiology Holdings, Inc. from March 2005 to March 2008. Mr. Mayleben was formerly the Chief Operating Officer of Esperion Therapeutics, which later became a division of Pfizer Global Research & Development. He joined Esperion in late 1998 as Chief Financial Officer. While at Esperion, Mr. Mayleben led the raising of more than $200 million in venture capital and institutional equity funding and later negotiated the acquisition of Esperion by Pfizer in December 2003. Mr. Mayleben holds a Masters of Business Administration, with distinction, from the J.L. Kellogg Graduate School of Management at Northwestern University, and a Bachelor of Business Administration degree from the University of Michigan Ross School of Business. He is on the Advisory Board for the Wolverine Venture Fund and serves as a director for several private life science companies.

Alan Rubino

Mr. Alan L. Rubino is Independent Director of Aastrom Biosciences Inc. He recently assumed the CEO and President of Emisphere Technologies, Inc., a publicly-held company headquartered in Roseland, NJ. He and a new management team will be repositioning/transitioning the company from a drug-delivery company only firm, into a more expanded specialty pharma company that will continue to include new delivery system partnerships, NDA Rx and Rx medical food products at the commercial stage. Just prior to Emisphere, Mr. Rubino served as Chief Executive Officer and President of New American Therapeutics, Inc., a specialty pharmaceutical company, since October 2010 where he led the acquisition of penciclovir from Novartis AG. He and his team re-marketed the product and significantly advanced its sale, which resulted in a return to the company’s investors. Previously, Mr. Rubino served as the Chief Executive Officer and President of Akrimax Pharmaceuticals, LLC, an integrated specialty pharmaceutical company, since February 2008. Prior to this he served as President and Chief Operating Officer of Pharmos Corporation, a biopharmaceutical company, from November 2005 to December 2007. In addition, he was assigned to various executive committee roles in the areas of marketing, project management, and globalization of Roche Holdings. Mr. Rubino also held senior executive positions at PDI, Inc., a sales and marketing support company, and Cardinal Health, a company focused on improving the cost-effectiveness of health care, from 2001 to 2005. He received Bachelor of Arts degree in economics from Rutgers University with a minor in biology/chemistry and also completed post-graduate educational programs at the University of Lausanne and Harvard Business School. Additionally, he serves on the Board of Rutgers University School of Business and the Lerner Center for Pharmaceutical Studies.

Nelson Sims

Mr. Nelson M. Sims is Independent Director of Aastrom Biosciences Inc. He is a Director since February 2006 and was Chairman of the Board from 2007 through 2009. He served as the President and Chief Executive Officer (from 2003 through 2005) of Novavax, Inc., an international health and life science company. From 1973 through 2001, Mr. Sims served in various executive positions in sales, marketing, business development, and general management of Eli Lilly and Company, a pharmaceutical company, including Executive Director of Alliance Management, Vice President, Sales and Marketing of Hybritech, Inc. (which was acquired by Eli Lilly) and President of Eli Lilly Canada. Mr. Sims received a Bachelor of Science degree in Pharmacy from Southwestern Oklahoma State University, and completed the Tuck Executive Program at the Amos Tuck School of Business at Dartmouth College. In addition to serving as a board member of companies where he also led the executive management team, Mr. Sims has other board experience serving both public and private companies, including MDS, Inc., ATS Automation Tooling Systems, Inc. and Novavax, Inc. Currently, in addition to Aastrom, Mr. Sims sits on the board of Tosca, Inc.

Basic Compensation

Name Fiscal Year Total

Robert Zerbe

--

Dominick Colangelo

1,445,060

Gerard Michel

--

Daniel Orlando

412,197

Ross Tubo

--

David Recker

--

Heidi Hagen

--

Timothy Mayleben

1,326,890

Alan Rubino

--

Nelson Sims

--
As Of 30 Dec 2013
Search Stocks